Yanan Zhu
Stock Analyst at Wells Fargo
(2.00)
# 2,998
Out of 4,898 analysts
63
Total ratings
40%
Success rate
-6.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $100 → $75 | $19.23 | +290.02% | 3 | Jun 17, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $20 → $16 | $2.25 | +611.11% | 3 | May 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $50 → $45 | $13.31 | +238.09% | 7 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $1.5 → $1 | $0.28 | +255.87% | 3 | May 14, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $75 → $70 | $21.17 | +230.66% | 3 | May 7, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $2.65 | +126.42% | 3 | Mar 21, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | $3.44 | +191.12% | 2 | Mar 12, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.14 | +250.88% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $14.55 | +106.19% | 2 | Feb 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $60 → $50 | $11.95 | +318.41% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $2.85 | +40.35% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $136 → $32 | $8.66 | +269.52% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $42.55 | +80.96% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $16.41 | +143.75% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $56.42 | +15.21% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.34 | +798.20% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $2.01 | +1,143.78% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $33.58 | +48.90% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.50 | +700.00% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $4.00 | +11,150.00% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $2.64 | +279.51% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $561.28 | -41.92% | 1 | Feb 2, 2021 |
Sarepta Therapeutics
Jun 17, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $19.23
Upside: +290.02%
Metagenomi
May 14, 2025
Maintains: Overweight
Price Target: $20 → $16
Current: $2.25
Upside: +611.11%
Arcturus Therapeutics Holdings
May 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $13.31
Upside: +238.09%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.28
Upside: +255.87%
Beam Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $21.17
Upside: +230.66%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $2.65
Upside: +126.42%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.44
Upside: +191.12%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.14
Upside: +250.88%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $14.55
Upside: +106.19%
Intellia Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $11.95
Upside: +318.41%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $2.85
Upside: +40.35%
Nov 12, 2024
Maintains: Overweight
Price Target: $136 → $32
Current: $8.66
Upside: +269.52%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $42.55
Upside: +80.96%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $16.41
Upside: +143.75%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $56.42
Upside: +15.21%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $3.34
Upside: +798.20%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $2.01
Upside: +1,143.78%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $33.58
Upside: +48.90%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.50
Upside: +700.00%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $4.00
Upside: +11,150.00%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.64
Upside: +279.51%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $561.28
Upside: -41.92%